- Home
- ALTO vs TLSA Comparison
ALTO vs TLSA Comparison
Compare ALTO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | TLSA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 192.1M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALTO | TLSA |
|---|---|---|
| Price | $2.28 | $1.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 629.3K | 139.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $965,258,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.73 |
| 52 Week High | $3.18 | $2.60 |
Technical Indicators
Market Signals| Indicator | ALTO | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 51.28 |
| Support Level | $0.99 | $1.30 |
| Resistance Level | $2.91 | $1.50 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 4.07 | 85.71 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.